{"id":"gliclazide-comparison-drug","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Weight gain"},{"rate":"1-3","effect":"Gastrointestinal disturbances"},{"rate":"1-2","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL427216","moleculeType":"Small molecule","molecularWeight":"323.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gliclazide is a meglitinide-class sulfonylurea that binds to ATP-sensitive potassium channels on pancreatic beta cells, causing cell depolarization and opening of voltage-gated calcium channels. This influx of calcium triggers the release of stored insulin into the bloodstream, thereby lowering blood glucose levels in patients with type 2 diabetes.","oneSentence":"Gliclazide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:16.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06217887","phase":"NA","title":"Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-05-10","conditions":"Type 2 Diabetes Mellitus, Cognitive Function Abnormal","enrollment":58},{"nctId":"NCT03246828","phase":"NA","title":"Glucagon in MODY (Maturity Onset Diabetes of the Young)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2017-07-03","conditions":"MODY1, MODY3","enrollment":10},{"nctId":"NCT02925559","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2016-10","conditions":"Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT03467945","phase":"PHASE1","title":"Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-02-16","conditions":"Healthy","enrollment":40},{"nctId":"NCT00102388","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1092},{"nctId":"NCT01679899","phase":"PHASE4","title":"Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability","status":"COMPLETED","sponsor":"Centro de Diabetes Curitiba Ltda","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus, Menopause, Osteoporosis","enrollment":56},{"nctId":"NCT02587741","phase":"EARLY_PHASE1","title":"Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetic Retinopathy","enrollment":600},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT01584232","phase":"PHASE3","title":"A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-04","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01022762","phase":"PHASE4","title":"Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":440},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT01195532","phase":"","title":"An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2010-01","conditions":"Hyperglycemia, Diabetes","enrollment":40},{"nctId":"NCT00225342","phase":"PHASE4","title":"Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina","status":"WITHDRAWN","sponsor":"University of Glasgow","startDate":"","conditions":"Angina Pectoris, Diabetes Mellitus, Type 2","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gliclazide (Comparison drug)","genericName":"Gliclazide (Comparison drug)","companyName":"University of Glasgow","companyId":"university-of-glasgow","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gliclazide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}